Fidelity International’s TG Therapeutics TGTX Stock Holding History

Fidelity International’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-49,907	Closed	-$888K	–	979
2024 Q2	$888K	Buy	49,907 +3,407	+7%	+$54.4K	﹤0.01%	726
2024 Q1	$707K	Buy	46,500 +3,274	+8%	+$52.2K	﹤0.01%	741
2023 Q4	$738K	Buy	+43,226	New	+$502K	﹤0.01%	722
2023 Q3	–	Sell	-114,412	Closed	-$2.84M	–	848
2023 Q2	$2.84M	Buy	114,412 +5,375	+5%	+$139K	﹤0.01%	610
2023 Q1	$1.64M	Buy	+109,037	New	+$1.66M	﹤0.01%	681
2021 Q4	–	Sell	-170,707	Closed	-$5.68M	–	855
2021 Q3	$5.68M	Sell	170,707 -6,656	-4%	-$206K	0.01%	585
2021 Q2	$6.88M	Buy	177,363 +32,842	+23%	+$1.29M	0.01%	603
2021 Q1	$6.97M	Buy	+144,521	New	+$6.94M	0.01%	564

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity International's TGTX Position: Q3 2024 in Review

Fidelity International sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 49,907 shares — an estimated $888K sold.

Fidelity International first reported a position in TGTX in Q1 2021 and held it in 8 quarters. The position peaked at $6.97M in Q1 2021. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

Fidelity International reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
Fidelity International sold 49,907 TG Therapeutics shares in Q3 2024, an estimated $888K.
Fidelity International first reported a position in TG Therapeutics in Q1 2021 and held it in 8 quarters.
Fidelity International's TG Therapeutics position peaked at $6.97M in Q1 2021.
308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Fidelity International's 13F filing for Q3 2024, filed 13 Nov 2024.